EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antibiotic resistance in community-acquired urinary tract infections. Did the COVID-19 pandemic cause a change?

Emine Unal Evren, Hakan Evren, Nilufer Galip

The Journal of Infection in Developing Countries · 2024

DOI: 10.3855/jidc.18844 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2024. Verfasst von Emine Unal Evren und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology; School of Medicine, University of Kyrenia, Kyrenia, Cyprus. Hauptthemen laut MEDLINE: COVID-19, Community-Acquired Infections, Urinary Tract Infections, Anti-Bacterial Agents. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study aimed to evaluate the antimicrobial resistance rates before and during the coronavirus disease 2019 (COVID-19) pandemic. Methodology: 897 positive urine cultures collected from outpatients of all ages between January 1, 2017, and December 31, 2022, were analyzed. The antibiotic susceptibility tests (AST) were analyzed by using an automated VITEK 2 (Biomerieux, Marcy-l`Étoile, France) compact system. AST results were interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria. The significance of resistance rates was tested with the Pearson’s Chi-squared test and risk factors of extended-spectrum beta-lactamases (ESBL) positiveness were identified with binary logistic regression.

Results

E. coli (n = 774) and K. pneumoniae (n = 123) were isolated in 86.3% and 13.7% of the patients, respectively. During this period of six years before and during pandemic, the highest resistance rate was found for cefuroxime axetil (49.8%) and the lowest for nitrofuratoin (6.0%). Statistically significant increases in resistance compared to the pre-pandemic period were only determined for cefixime (37.2 vs 46.0%) and ceftriaxone (37.6 vs 46.1%) (p = 0.010). ESBL positivity was the most important factor that statistically increased resistance for all antibiotics (p < 0.001 for all). Being male [OR (95% CI) 1.56 (1.13-2.15)] and presenting to the clinic after the pandemic period [1.4 (1.1-1.8)] were found to increase ESBL positiveness significantly.

Conclusions

Ceftriaxone and Cefixime resistance rates and ESBL positivity among the uropathogens E. coli and K. pneumoniae increased during the pandemic compared with the pre-pandemic period. ESBL positivity was higher in males.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Community-Acquired InfectionsUrinary Tract InfectionsAnti-Bacterial AgentsMicrobial Sensitivity TestsHumansMaleFemaleMiddle AgedAdultAgedEscherichia coliDrug Resistance, BacterialYoung AdultAdolescentKlebsiella pneumoniaeAged, 80 and overSARS-CoV-2Escherichia coli InfectionsPandemicsChild

Stichwörter der Autor:innen

COVID-19pandemicresistanceuropathogen

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases and Clinical Microbiology; School of Medicine, University of Kyrenia, Kyrenia, Cyprus.
  • Division of Allergy and Immunology, Department of Pediatrics; School of Medicine, University of Kyrenia, Kyrenia, Cyprus.

Zitieren

APA

Unal Evren, E., Evren, H., & Galip, N. (2024). Antibiotic resistance in community-acquired urinary tract infections. Did the COVID-19 pandemic cause a change?. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.18844

Vancouver

Unal Evren E, Evren H, Galip N. Antibiotic resistance in community-acquired urinary tract infections. Did the COVID-19 pandemic cause a change?. The Journal of Infection in Developing Countries. 2024. doi:10.3855/jidc.18844

BibTeX
@article{UnalEvren2024,
  author = {Unal Evren, Emine and Evren, Hakan and Galip, Nilufer},
  title = {Antibiotic resistance in community-acquired urinary tract infections. Did the COVID-19 pandemic cause a change?},
  journal = {The Journal of Infection in Developing Countries},
  year = {2024},
  doi = {10.3855/jidc.18844}
}
Kostenlos starten →